Humanigen, Inc. (HGEN)

0.3462 -0.0228 (-6.18%) At close: 04:00PM EDT

Humanigen, Inc.

830 Morris Turnpike
4th Floor
Short Hills, NJ 07078-2625
United States
973 200 3100
https://www.humanigen.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 11

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Cameron Durrant M.D., MBA	Chairman & CEO	843.04k	N/A	1960
Mr. Timothy E. Morris C.P.A., CPA	CFO & COO	624.78k	N/A	1961
Dr. Dale Chappell M.B.A., M.D., MBA	Chief Scientific Officer & Director	N/A	N/A	1970
Dr. Adrian Kilcoyne M.B.A., M.D., M.P.H.	Chief Medical Officer	519.26k	N/A	1971
Mr. Kenneth Eugene Trbovich C.F.A.	Sr. VP of Investor Relations	N/A	N/A	N/A
Mr. Robert Atwill M.B.A.	Sr. VP and Head of Asia-Pacific Region & Bus. Devel.	N/A	N/A	N/A
Mr. Edward P. Jordan M.B.A.	Chief Commercial Officer	N/A	N/A	1968

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ‘cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is also being studied in conjunction with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1. Ifabotuzumab has been evaluated in a Phase 1 study of glioblastoma multiforme that showed tumor specific targeting of all known tumor sites with no normal tissue uptake. HGEN005 is being explored as a treatment for a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey.

Corporate Governance

Humanigen, Inc.’s ISS Governance QualityScore as of July 31, 2022 is 7. The pillar scores are Audit: 8; Board: 8; Shareholder Rights: 3; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.